Growth Hormone Therapy Effective at Increasing Anemics' Height During Childhood

Article

For children with Diamond-Blackfan Anemia (DBA) - an inherited condition defined by low red blood cell counts and limited progenitor cells in the bone marrow - growth hormone (GH) therapy was found to increase the short stature of patients - a symptom not widely analyzed.

For children with Diamond-Blackfan Anemia (DBA) — an inherited condition defined by low red blood cell counts and limited progenitor cells in the bone marrow — growth hormone (GH) therapy was found to increase the short stature of patients — a symptom not widely analyzed.

Commonly born smaller than average, GBA patients often experienced cellular mutations that often go undiscovered. Also experiencing iron overload, previous research has implicated this factor in GBA (and other chronic anemia) patients’ decreased growth rates despite secreting adequate amounts of GHs.

For their study, Jonathan C. Howell, MD, PhD, and his colleagues analyzed the annual growth velocity (GV) and height-for-age Z-scores (HAZ) of 44 DBA patients aged 2-20 years-old who did not undergo GH therapy. Investigators compared the height information with 19 DBA patients receiving hormones (mean dose 0.3 mg/kg/week, range 0.2 to 0.4 mg/kg/week).

While investigators documented that the GH patients were shorter than subjects not treated before their regimen began, they experienced a significant increase in their rate of growth within the first 2 years of their therapy. For every 4 years of treatment, the researchers noted that GH participants’ HAZ scores were better than baseline standards.

“Additionally, after 2 years of GH treatment, HAZ scores were not significantly different from the control DBA population, indicating successful catch-up growth relative to peers with DBA,” the authors also reported in Pediatric Blood Cancer.

In light of their discovery, the investigators pressed for the use of personalized growth charts for DBA patients to identify which patients would make good GH therapy candidates.

“Based both on the frequent occurrence of short stature in children with DBA, and on data presented here, we recommend careful consideration of GH therapy at a young age for those patients with DBA who have significant short stature to improve GV and overall HAZ scores,” the writers also recommended.

Recent Videos
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Lucas Harrington, PhD, the cofounder and chief scientific officer of Mammoth Biosciences
Stephanie Tagliatela on Researching AAV for Lennox-Gastaut, Alzheimer Disease, SCN9a Pain
Miloš Miljković, MD, on mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Jacques Galipeau, MD, on Working to Streamline Cell and Gene Therapy Development
© 2024 MJH Life Sciences

All rights reserved.